Vaccination in Solid Organ Transplant Recipients
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 3631
Special Issue Editor
2. Department of Vascular Biology of the Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse 3, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1048, Toulouse, France
Interests: kidney transplantation; liver transplantation; transplant immunology
Special Issue Information
Dear Colleagues,
Solid Organ Transplant candidates or recipients are a high risk population for many infections, while some of them are vaccine preventable diseases. Covid-19 pandemic reminded us the altered immune vaccine response in transplant recipients, with dramatical consequences. Hence, every effort should be made as soon as possible, prior transplantation. Recommendations for immunization of transplant patients concerning several frequent infections exist (e.g., Influenza, Tetanos, Polio, Pertussis, etc.).
Nonetheless, substantial patients remain incompletely or unvaccinated. This leads to avoidable health problems. Moreover, prevention treatments by vaccine remain an unmet medical need for some infections (such as cytomegalovirus).
In this Special Issue of Vaccine, we focus on recent progresses made in the field of vaccinology, as well as future directions identified for solid organ transplant patients. Based on your extensive knowledge and experience, we invite you to contribute with an original report, personal point of vue, or review to highlight (i) specific organization models proposed to improve vaccination rate in this population, (ii) immune pathways developed to improve immunogenicity of vaccines or alternative strategies for transplant recipients, (iii) future directions concerning the development of new vaccines.
Dr. Arnaud Del Bello
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cytomegalovirus
- sars-CoV-2 infection
- solid organ transplant recipients
- pneumococcal vaccine
- HHV-6
- HHV-8
- HSV
- HPV
